These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27347468)

  • 1. Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry.
    Song CH; Han JW
    Springerplus; 2016; 5(1):692. PubMed ID: 27347468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patent cliff mitigation strategies: giving new life to blockbusters.
    Kakkar AK
    Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drug: Development trends and strategies.
    Sharma A; Jacob A; Tandon M; Kumar D
    J Pharm Bioallied Sci; 2010 Oct; 2(4):290-9. PubMed ID: 21180460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Patent Expiry on the Performance of Innovator Multinational Pharmaceutical Companies in a Low Middle Income Country.
    Khalil F; Onyango JO
    Front Med Technol; 2022; 4():783460. PubMed ID: 35445207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing model of big pharma: impact of key trends.
    Gautam A; Pan X
    Drug Discov Today; 2016 Mar; 21(3):379-84. PubMed ID: 26477304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 11. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent term restoration for top-selling drugs in the United States.
    Beall RF; Darrow JJ; Kesselheim AS
    Drug Discov Today; 2019 Jan; 24(1):20-25. PubMed ID: 30055271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms.
    Vertès AA
    Regen Med; 2014; 9(4):479-95. PubMed ID: 25159065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
    Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
    Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovation strategies for generic drug companies: moving into supergenerics.
    Ross MS
    IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.